BEHANDLUNG VON AUTOIMMUNERKRANKUNGEN

Patent europeic · EP3145931 · En vigur

Inscripziun en il register

Numer da publicaziun
EP3145931
Numer da la dumonda
EP15795527
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
En vigur
Scrittira da patent
Concedì
Annunzià
22-05-2015
Publitgà
29-03-2017
Concedì
31-03-2021
La protecziun finescha il pli tard
21-05-2035
Proxima taxa annuala scadenta
31-05-2027
Classas IPC
C07D 487/04 (2006.01)
C07D 403/00 (2006.01)
A01N 43/54 (2006.01)
A61K 31/496 (2006.01)
A61K 31/506 (2006.01)
A61K 31/04 (2006.01)
A61P 37/06 (2006.01)
Prioritad
US 201462002724 P 23.05.2014
Dumonda PCT
PCT/US2015/032315 22.05.2015
Publicaziun PCT
WO2015/179847 26.11.2015
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 01-06-2026

    Midada

    Published in Swissreg on 01.06.2026

  2. 01-06-2025

    Midada

    Published in Swissreg on 01.06.2025

  3. 02-06-2024

    Midada

    Published in Swissreg on 02.06.2024

  4. 09-06-2023

    Midada

    Published in Swissreg on 09.06.2023

  5. 09-02-2022

    Midada

    Published in Swissreg on 09.02.2022

  6. 31-03-2021

    Concedì

    Published in Swissreg on 31.03.2021

Partidas

Possessur

Mingsight Pharmaceuticals, Inc.

P.O. Box 261208, San Diego, CA 92196, US

Inventur

ZHANG, Kai

San Diego, California 92196, US

NIESMAN, Michael

San Diego, CA 92196, US

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.